Scarica l'app Stockscreener
11.57
4.30%
-0.52
Dopo l'orario di chiusura:
11.74
0.17
+1.47%
Precedente Chiudi:
$12.09
Aprire:
$12
Volume 24 ore:
1.81M
Relative Volume:
1.01
Capitalizzazione di mercato:
$1.03B
Reddito:
$71.64M
Utile/perdita netta:
$-294.57M
Rapporto P/E:
-3.4558
EPS:
-3.348
Flusso di cassa netto:
$-84.46M
1 W Prestazione:
-12.02%
1M Prestazione:
+17.46%
6M Prestazione:
+24.95%
1 anno Prestazione:
+41.62%
Intervallo 1D:
$11.44
$12.00
Intervallo di 1 settimana:
$11.44
$13.27
Portata 52W:
$7.3575
$13.90
Kura Oncology Inc Stock (KURA) Company Profile
Nome
Kura Oncology Inc
Settore
Industria
Telefono
(858) 500-8800
Indirizzo
4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA
Compare KURA vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
11.57 | 1.08B | 71.64M | -294.57M | -84.46M | -3.348 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-14 | Iniziato | Lake Street | Buy |
| 2025-09-04 | Iniziato | Guggenheim | Neutral |
| 2025-02-06 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-10-14 | Downgrade | Stifel | Buy → Hold |
| 2023-12-22 | Iniziato | Mizuho | Buy |
| 2023-08-11 | Iniziato | BofA Securities | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Perform |
| 2023-05-17 | Iniziato | BTIG Research | Buy |
| 2023-01-31 | Iniziato | Stifel | Buy |
| 2022-07-12 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-02-15 | Iniziato | Jefferies | Buy |
| 2021-05-05 | Ripresa | Credit Suisse | Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-12-07 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-03 | Iniziato | Stifel | Buy |
| 2020-11-05 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Iniziato | Credit Suisse | Outperform |
| 2020-05-05 | Iniziato | Barclays | Overweight |
| 2019-07-18 | Iniziato | Deutsche Bank | Buy |
| 2018-11-09 | Iniziato | Piper Jaffray | Overweight |
| 2018-08-01 | Iniziato | H.C. Wainwright | Buy |
| 2016-10-13 | Ripresa | Leerink Partners | Outperform |
| 2016-01-22 | Iniziato | JMP Securities | Mkt Outperform |
| 2015-12-30 | Iniziato | Oppenheimer | Outperform |
| 2015-12-16 | Iniziato | Citigroup | Buy |
Mostra tutto
Kura Oncology Inc Borsa (KURA) Ultime notizie
Kura Oncology (KURA) awards CFO 450,000 stock options - Stock Titan
Kura Oncology (KURA) CFO files initial ownership report with no trades - Stock Titan
Kura Spins Out Caspian With $50m To Test Menin Inhibition In Diabetes - insights.citeline.com
Kura assets flow to Caspian for cardiometabolic indications - BioWorld News
Kura Oncology Raises $50M for Cardiometabolic Subsidiary Caspian - minichart.com.sg
KURA Oncology Launches Caspian Therapeutics, Shifting Focus Whil - GuruFocus
Kura Oncology at cantor conference: rapid launch, wider ambitions By Investing.com - Investing.com India
Kura Oncology Pivots Diabetes Strategy Into $50 Million Subsidiary - TradingView
Kura Oncology, Inc. Enters into Contribution and License and Intercompany Services Agreement with Caspian Therapeutics, Inc - marketscreener.com
Kura Oncology Launches Caspian Therapeutics With $50 Million Funding - marketscreener.com
Kura Oncology Establishes Caspian Partnership for Cardiometabolic Focus - TipRanks
Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes - The Manila Times
KURA: Strong commercial momentum and advancing late-stage pipeline position for major growth - TradingView
KURA: Strong commercial momentum and advancing late-stage pipeline position for major growth by 2028 - TradingView
Kura Oncology at Wells Fargo conference: launch gains and pipeline breadth - Investing.com
Kura Oncology Names Jennifer Fulk as Chief Financial Officer Effective September 8, 2026 - Kalkine Media
Kura Oncology Names Jennifer Fulk Chief Financial Officer - Minichart
Kura Oncology, Inc. Announces Chief Financial Officer Changes, Effective September 8, 2026 - marketscreener.com
Kura Oncology Names Jennifer Fulk Finance Chief - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
Jennifer Fulk named CFO of Kura Oncology, replacing Troy E. Wilson and Thomas Doyle - TradingView
A former Eli Lilly executive takes Kura's top finance job - Stock Titan
Four new hires get options to buy 48,450 Kura shares - Stock Titan
Kura Oncology Inc (KURA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Price-Driven Insight from (KURA) for Rule-Based Strategy - Stock Traders Daily
Kura Oncology (KURA) Stock Looks Fully Priced After Its 56% Run - finance.yahoo.com
KURA Stock Gains 37.6% in a Month: Here's What You Need to Know - TradingView
Kura Oncology to Participate in Three Investor Conferences in September - GlobeNewswire
Kura Oncology (KURA) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Mizuho Securities Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Cancer Biotech Kura Oncology Rallies to New High After CEO’s Stock Purchase - Barron's
Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves - finance.yahoo.com
Kura Oncology (KURA) Moves 8.3% Higher: Will This Strength Last? - qz.com
Kura Oncology: 'Strong Buy': Ziftomenib AML Expansions With Different Regimens Could Boost KOMZIFTI's Prospects - Seeking Alpha
Kura Oncology Shares Rise After CEO Purchases 100,000 Shares - marketscreener.com
Kura Oncology stock jumps after CEO buys $1.24M in shares - Investing.com Nigeria
Kura Oncology CCO Brian Powl sells $51,663 in shares By Investing.com - Investing.com Nigeria
Kura Oncology CEO Troy Wilson buys $1.24 million Kura shares By Investing.com - Investing.com South Africa
The $1.24 Billion Reason Why Kura Oncology Stock Is Up Today - webull.com
Citizens reiterates Kura Oncology stock rating on launch progress - Investing.com
UBS Remains a Buy on Kura Oncology (KURA) - The Globe and Mail
Kura Oncology (KURA) Chief Legal Officer Teresa Bair Sells 31,48 - GuruFocus
Kura Oncology (NASDAQ:KURA) Insider Sells 31,487 Shares - MarketBeat
Kura Oncology (NASDAQ: KURA) affiliate flags 4,345-share Rule 144 sale - Stock Titan
Kura Oncology (KURA) counsel offloads shares via 10b5-1 plan - Stock Titan
Great Lakes Advisors LLC Invests $2.85 Million in Kura Oncology, Inc. $KURA - MarketBeat
Kura Oncology (KURA) Q2 2026 Earnings Call Transcript - The Globe and Mail
Kura Oncology (NASDAQ: KURA) exec plans to sell 31,487 shares - Stock Titan
Kura Oncology (KURA) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
Kura Oncology (NASDAQ:KURA) Gains Traction With Its AML Menin Inhibitor - Kalkine Media
Troy Wilson Bought 12% More Shares In Kura Oncology - simplywall.st
Kura Oncology Inc Azioni (KURA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):